company background image
AFT logo

AFT Pharmaceuticals NZSE:AFT Stock Report

Last Price

NZ$2.65

Market Cap

NZ$274.7m

7D

6.9%

1Y

-20.9%

Updated

21 Nov, 2024

Data

Company Financials +

AFT Pharmaceuticals Limited

NZSE:AFT Stock Report

Market Cap: NZ$274.7m

AFT Stock Overview

Engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. More details

AFT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance5/6
Financial Health6/6
Dividends0/6

AFT Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AFT Pharmaceuticals
Historical stock prices
Current Share PriceNZ$2.65
52 Week HighNZ$3.85
52 Week LowNZ$2.37
Beta0.37
11 Month Change-20.18%
3 Month Change-18.71%
1 Year Change-20.90%
33 Year Change-45.25%
5 Year Change-15.06%
Change since IPO-14.52%

Recent News & Updates

AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 17
AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Jul 26
It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Recent updates

AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 17
AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Jul 26
It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25
AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

May 22
Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Oct 17
Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

May 23
Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

Dec 01
Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30
We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02
With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20
Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13
A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23
Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02
Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12
Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21
AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Shareholder Returns

AFTNZ PharmaceuticalsNZ Market
7D6.9%-11.4%0.1%
1Y-20.9%34.7%9.6%

Return vs Industry: AFT underperformed the NZ Pharmaceuticals industry which returned 34.7% over the past year.

Return vs Market: AFT underperformed the NZ Market which returned 9.6% over the past year.

Price Volatility

Is AFT's price volatile compared to industry and market?
AFT volatility
AFT Average Weekly Movement4.8%
Pharmaceuticals Industry Average Movement11.9%
Market Average Movement4.5%
10% most volatile stocks in NZ Market9.3%
10% least volatile stocks in NZ Market3.0%

Stable Share Price: AFT has not had significant price volatility in the past 3 months compared to the NZ market.

Volatility Over Time: AFT's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997110Hartley Atkinsonwww.aftpharm.com

AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

AFT Pharmaceuticals Limited Fundamentals Summary

How do AFT Pharmaceuticals's earnings and revenue compare to its market cap?
AFT fundamental statistics
Market capNZ$274.75m
Earnings (TTM)NZ$15.61m
Revenue (TTM)NZ$195.41m

17.8x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AFT income statement (TTM)
RevenueNZ$195.41m
Cost of RevenueNZ$107.14m
Gross ProfitNZ$88.27m
Other ExpensesNZ$72.66m
EarningsNZ$15.61m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.15
Gross Margin45.17%
Net Profit Margin7.99%
Debt/Equity Ratio32.1%

How did AFT perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

11%

Payout Ratio